Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679609 | 0.86 | ALDH1A1 (0.46) | KMT2AMEN1ALDH1A1KDM4ELMNA | |
| SCHEMBL6658878 | 0.86 | HRH3 (0.36) | ALDH1A1LMNAGAAHTTPAOX | |
| SCHEMBL6659624 | 0.86 | HRH3 (0.42) | PAOXHRH3ALOX15 | |
| SCHEMBL21934600 | 0.86 | HRH3 (0.36) | ALDH1A1LMNAGAAHTTPAOX | |
| SCHEMBL6662182 | 0.84 | HRH3 (0.46) | PAOXHRH3 | |
| SCHEMBL9611073 | 0.81 | ALOX15 (0.36) | ALDH1A1KDM4ESMN1; SMN2ALOX15 | |
| SCHEMBL6656278 | 0.81 | ALOX15 (0.36) | ALDH1A1KDM4ESMN1; SMN2ALOX15 | |
| SCHEMBL972563 | 0.81 | KDM4E (0.46) | KMT2AMEN1ALDH1A1KDM4ELMNA | |
| SCHEMBL1616084 | 0.81 | — | — | |
| SCHEMBL10294010 | 0.80 | HTR1A (0.48) | KMT2AMEN1ALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023139199-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-07-27 | — | — | WO | disclosed |
| US-20220220069-A1 | COMPOUND USED AS SIRT6 SMALL-MOLECULE ALLOSTERIC ACTIVATOR AND PHARMACEUTICAL COMPOSITION THEREOF | SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE (CN) | 2022-07-14 | — | — | US | disclosed |
| EP-3841100-A1 | PROTEOLYSIS TARGETING CHIMERIC (PROTAC) COMPOUND WITH E3 UBIQUITIN LIGASE BINDING ACTIVITY AND TARGETING ALPHA-SYNUCLEIN PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES | Arvinas Operations, Inc. (US) | 2021-06-30 | — | — | EP | disclosed |
| WO-2020041331-A1 | PROTEOLYSIS TARGETING CHIMERIC (PROTAC) COMPOUND WITH E3 UBIQUITIN LIGASE BINDING ACTIVITY AND TARGETING ALPHA-SYNUCLEIN PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES | ARVINAS OPERATIONS, INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| US-20190322661-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-10-24 | — | — | US | disclosed |
| US-10245261-B2 | Substituted indol-5-ol derivatives and their therapeutic applications | NANTBIO, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10227340-B2 | Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180208603-A1 | HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANT HOLDINGS IP, LLC | 2018-07-26 | — | — | US | disclosed |
| US-20180072712-A1 | THIAZOLYL- OR THIADIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180072712-A1 | THIAZOLYL- OR THIADIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
| US-20120202818-A1 | UREIDOPHENYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120196860-A1 | Triazine derivatives and their therapeutical applications | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-08-02 | — | — | US | disclosed |
| EP-2475649-A1 | INDENONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Korea Research Institute Of Chemical Technology (KR) | 2012-07-18 | — | — | EP | disclosed |
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-05 | — | — | US | disclosed |
| US-20110281866-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110150763-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, LLC (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2011030955-A1 | INDENONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2011-03-17 | — | — | WO | disclosed |
| US-7858782-B2 | Triazine derivatives and their therapeutical applications | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-28 | — | — | US | disclosed |
| US-20080176853-A1 | e.g. N-(2-chloro-6-methylphenyl)-3-ethoxyacrylamide; protein (tyrosine and serine/threonine) kinase inhibitor; variety of conditions and diseases; antiproliferative, anticarcinogenic, antiinflammatory, antiallergenic agent; autoimmune and neurodegenerative disorders | ABRAXIS BIOSCIENCE, INC. (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220069-A1 | COMPOUND USED AS SIRT6 SMALL-MOLECULE ALLOSTERIC ACTIVATOR AND PHARMACEUTICAL COMPOSITION THEREOF | SIRT6, SIRT1, SIRT7 | KMT2A 158/4885MEN1 2009/4885ALDH1A1 2446/4885 |
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CYP3A5, CYP11B2, ABCB1 | KMT2A 2489/4885MEN1 3723/4885ALDH1A1 213/4885 |
| US-20190322661-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, FLT3 | KMT2A 585/4885MEN1 1979/4885ALDH1A1 729/4885 |
| US-20180072712-A1 | THIAZOLYL- OR THIADIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | IRAK4, IRAK1, IRAK3 | KMT2A 1241/4885MEN1 3304/4885ALDH1A1 3990/4885 |
| US-10245261-B2 | Substituted indol-5-ol derivatives and their therapeutic applications | GRK5, GRK3, CDK5 | KMT2A 2312/4885MEN1 3843/4885ALDH1A1 2582/4885 |
| US-10227340-B2 | Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors | IRAK4, IRAK1, IRAK3 | KMT2A 1241/4885MEN1 3304/4885ALDH1A1 3990/4885 |
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | STK25, STK35, SGK2 | KMT2A 1102/4885MEN1 4391/4885ALDH1A1 3351/4885 |
| US-20180208603-A1 | HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | TPMT, MKI67, TST | KMT2A 3192/4885MEN1 1876/4885ALDH1A1 325/4885 |
| US-20120196860-A1 | Triazine derivatives and their therapeutical applications | MAP3K2, MAP3K5, MAP4K2 | KMT2A 1227/4885MEN1 4490/4885ALDH1A1 3921/4885 |
| US-20110281866-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K13, MAP3K3, CDK3 | KMT2A 1279/4885MEN1 1612/4885ALDH1A1 3979/4885 |
| US-20110150763-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | BAZ2A, CAMKK2, BAZ1A | KMT2A 1241/4885MEN1 4476/4885ALDH1A1 3429/4885 |
| US-20120202818-A1 | UREIDOPHENYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | UCK2, ULK2, ULK1 | KMT2A 1883/4885MEN1 4367/4885ALDH1A1 3580/4885 |
| US-20080176853-A1 | e.g. N-(2-chloro-6-methylphenyl)-3-ethoxyacrylamide; protein (tyrosine and serine/threonine) kinase inhibitor; variety of conditions and diseases; antiproliferative, anticarcinogenic, antiinflammatory, antiallergenic agent; autoimmune and neurodegenerative disorders | MAP3K15, DSTYK, STK25 | KMT2A 790/4885MEN1 2868/4885ALDH1A1 4099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.